Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seungwon Kim

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
Virus Evolution|October 14, 2024
Intra- and inter-subtype HIV diversity between 1994 and 2018 in southern Uganda: a longitudinal population-based studySeungwon Kim, Godfrey Kigozi, Michael A Martin, et al.
World Journal of Otorhinolaryngology - Head and Neck Surgery|December 7, 2022
A phase Ⅱ prospective trial of photobiomodulation therapy in limiting oral mucositis in the treatment of locally advanced head and neck cancer patientsJanielle K-A Taylor, Leila J Mady, Khalil Baddour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival BenefitMarco A Mascarella, Tolani F Olonisakin, Purva Rumde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2014
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancerNeil D Gross, Julie E Bauman, William E Gooding, et al.
Nature Communications|June 8, 2021
B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinomaAyana T Ruffin, Anthony R Cillo, Tracy Tabib, et al.
Head & Neck|April 25, 2020
Transition to a virtual multidisciplinary tumor board during the COVID-19 pandemic: University of Pittsburgh experienceHarish Dharmarajan, Jennifer L Anderson, Seungwon Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2025
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx CancerBarbara Burtness, Yael Flamand, Harry Quon, et al.
Nature Communications|December 18, 2021
Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencingCornelius H L Kürten, Aditi Kulkarni, Anthony R Cillo, et al.
JCI Insight|March 30, 2017
Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancerJulie E Bauman, Umamaheswar Duvvuri, William E Gooding, et al.
Hepatology (Baltimore, Md.)|November 13, 2021
A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiomeEun Ran Kim, Jeong Su Park, Jin Hee Kim, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
Virus Evolution|October 14, 2024
Intra- and inter-subtype HIV diversity between 1994 and 2018 in southern Uganda: a longitudinal population-based studySeungwon Kim, Godfrey Kigozi, Michael A Martin, et al.
World Journal of Otorhinolaryngology - Head and Neck Surgery|December 7, 2022
A phase Ⅱ prospective trial of photobiomodulation therapy in limiting oral mucositis in the treatment of locally advanced head and neck cancer patientsJanielle K-A Taylor, Leila J Mady, Khalil Baddour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival BenefitMarco A Mascarella, Tolani F Olonisakin, Purva Rumde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2014
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancerNeil D Gross, Julie E Bauman, William E Gooding, et al.
Nature Communications|June 8, 2021
B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinomaAyana T Ruffin, Anthony R Cillo, Tracy Tabib, et al.
Head & Neck|April 25, 2020
Transition to a virtual multidisciplinary tumor board during the COVID-19 pandemic: University of Pittsburgh experienceHarish Dharmarajan, Jennifer L Anderson, Seungwon Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2025
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx CancerBarbara Burtness, Yael Flamand, Harry Quon, et al.
Nature Communications|December 18, 2021
Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencingCornelius H L Kürten, Aditi Kulkarni, Anthony R Cillo, et al.
JCI Insight|March 30, 2017
Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancerJulie E Bauman, Umamaheswar Duvvuri, William E Gooding, et al.
Hepatology (Baltimore, Md.)|November 13, 2021
A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiomeEun Ran Kim, Jeong Su Park, Jin Hee Kim, et al.
Pageof 15